Loading...
XHKG6896
Market cap302mUSD
Jan 06, Last price  
3.18HKD
1D
0.32%
1Q
-0.31%
Jan 2017
6.00%
IPO
-31.91%
Name

Golden Throat Holdings Group Co Ltd

Chart & Performance

D1W1MN
XHKG:6896 chart
P/E
8.85
P/S
2.30
EPS
0.34
Div Yield, %
10.34%
Shrs. gr., 5y
—
Rev. gr., 5y
6.73%
Revenues
961m
-3.09%
548,857,000606,801,000706,922,000768,171,000624,084,000694,194,000797,129,000646,941,000820,543,000992,014,000961,377,000
Net income
250m
-11.04%
69,918,000121,893,000154,618,000102,912,00061,380,000102,186,000167,613,000154,052,000187,643,000281,218,000250,162,000
CFO
239m
-11.92%
180,860,000173,256,00051,235,00013,259,00079,902,000189,208,000215,590,000167,746,000164,889,000271,146,000238,838,000
Dividend
Jun 14, 20240.6 HKD/sh
Earnings
Jun 06, 2025

Profile

Golden Throat Holdings Group Company Limited, an investment holding company, manufactures and sells pharmaceutical, healthcare food, and other products in the People's Republic of China. It offers Golden Throat lozenges over-the-counter medicine to relive symptoms of sore and dry throat, and hoarse voice caused by acute pharyngitis. It also provides Golden Throat lozenge series products that include Dule lozenges and sugar-free Dule lozenges in various flavors, such as orange, fructus momordicae, chrysanthemum, American ginseng, and hawthorn; Yinxingye tablet, which is designed to facilitate blood circulation, remove blood stasis, and dredge energy channels; and herbal vegetable beverages for soothing voice and relieving sore throats. The company also exports its products to the United States, Canada, Russia, the European Union, Australia, Southeast Asia, the Middle East, Mexico, and Africa. Golden Throat Holdings Group Company Limited was founded in 1956 and is headquartered in Liuzhou, the People's Republic of China.
URL
http://www.goldenthroat.com/
IPO date
Jul 15, 2015
Employees
860
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
961,377
-3.09%
992,014
20.90%
Cost of revenue
624,638
634,891
Unusual Expense (Income)
NOPBT
336,739
357,123
NOPBT Margin
35.03%
36.00%
Operating Taxes
110,859
94,775
Tax Rate
32.92%
26.54%
NOPAT
225,880
262,348
Net income
250,162
-11.04%
281,218
49.87%
Dividends
(243,193)
(113,586)
Dividend yield
9.82%
8.04%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
412,340
272,586
Long-term debt
Deferred revenue
75
Other long-term liabilities
609
734
Net debt
(659,860)
(652,929)
Cash flow
Cash from operating activities
238,838
271,146
CAPEX
(17,539)
(15,847)
Cash from investing activities
(59,666)
36,585
Cash from financing activities
(79,383)
(142,008)
FCF
170,360
216,241
Balance
Cash
1,072,200
925,515
Long term investments
Excess cash
1,024,131
875,914
Stockholders' equity
113
863,701
Invested Capital
1,963,535
876,506
ROIC
15.91%
30.37%
ROCE
16.80%
20.23%
EV
Common stock shares outstanding
739,302
739,302
Price
3.35
75.39%
1.91
20.89%
Market cap
2,476,662
75.39%
1,412,067
20.89%
EV
1,816,802
759,138
EBITDA
375,772
395,767
EV/EBITDA
4.83
1.92
Interest
10,699
10,294
Interest/NOPBT
3.18%
2.88%